

**Listing of the claims**

1. (Previously presented). A pharmaceutical composition comprising a KPV dimer, a first preservative agent, a solvent, an alkalizer, an acrylic acid-based polymer, a second preservative agent and a gelatinizing agent.
2. (Previously presented). The composition of claim 1 further comprising a chelating agent.
3. (Previously presented). The composition of claim 1 wherein the KPV dimer is CKPV (SEQ ID NO: 5). dimer.
4. (Currently amended). The composition of claim 1 wherein the acrylic acid-based polymer is ~~Carbopol®~~ a high molecular weight, cross-linked, acrylic acid-based polymer.
5. (Previously presented). The composition of claim 1 wherein the first preservative is selected from the group consisting of phenoxyethanol, methylparaben, butylparaben, ethylparaben propylparaben and potassium sorbate and combinations thereof.
6. (Previously presented). The composition of claim 1 wherein the second preservative is selected from the group consisting of phenoxyethanol, methylparaben, butylparaben, ethylparaben propylparaben and potassium sorbate and combinations thereof
7. (Previously presented). The composition of claim 5 wherein the first preservative is methylparaben.
8. (Previously presented). The composition of claim 6 wherein the second preservative is propylparaben.
9. (Previously presented). The composition of claim 1 wherein the solvent is selected from the groups consisting of propylene glycol, ethanol, phenol, acetone, glycerol and isopropanol and combinations thereof.

10. (Previously presented). The composition of claim 9 wherein the solvent is propylene glycol.
11. (Previously presented). The composition of claim 2 wherein the chelating agent is selected from the group consisting of Coenzyme Q10, Zinc, L-Cysteine, L-Methionine, L-Lysine, Glutathione and EDTA and combinations thereof.
12. (Previously presented). The composition of claim 11 wherein the chelating agent is EDTA.
13. (Previously presented). The composition of claim 1 wherein the alkalizer is selected from the group consisting of HEPES, 2M NaOH, MES hydrate, MOPS, TAPS and Bis-Tris and combinations thereof.
14. (Previously presented). The composition of claim 13 wherein the alkalizer is NaOH.
15. (Previously presented). The composition of claim 1 wherein the gelatinizing agent is selected from the group consisting of water, sterile water, distilled water, sterile saline and sterile water for injection and combinations thereof.
16. (Previously presented). The composition of claim 15 wherein the gelatinizing agent is sterile water for injection.
17. (Previously presented). The composition of claim 3 wherein the CKPV (SEQ ID NO: 5). dimer is at least about 0.05-0.15% of the composition.
18. (Previously presented). The composition of claim 17 wherein the CKPV (SEQ ID NO: 5). dimer at least about 0.1% of the composition.
19. (Currently amended). The composition of claim 4 wherein the Carbopol® high molecular weight, cross-linked, acrylic acid-based polymer is at least about 1.5-2.5% of the composition.
20. (Currently amended). The composition of claim 19 wherein the Carbopol® high molecular weight, cross-linked, acrylic acid-based polymer is at least about 2% of the composition.

21. (Previously presented). The composition of claim 7 wherein the methylparaben is at least about 0.1-0.2% of the composition.

22. (Previously presented). The composition of claim 21 wherein the methylparaben is at least about 0.15% of the composition.

23. (Previously presented). The composition of claim 8 wherein the propylparaben is at least about 0.025-0.075% of the composition.

24. (Previously presented). The composition of claim 23 wherein the propylparaben is at least about 0.05% of the composition.

25. (Previously presented). The composition of claim 10 wherein the propylene glycol is at least about 5-15% of the composition.

26. (Previously presented). The composition of claim 25 wherein the propylene glycol is at least about 10% of the composition.

27. (Previously presented). The composition of claim 12 wherein the EDTA is at least about 0.05-0.15% of the composition.

28. (Previously presented). The composition of claim 27 wherein the EDTA is at least about 0.1% of the composition.

29. (Previously presented). The composition of claim 14 wherein the 2M NaOH is that quantity sufficient to bring the composition to a pH of 4.0,+-.0.1.

30. (Previously presented). The composition of claim 15 wherein the sterile water for injection is that quantity sufficient to create a gel.

31. (Currently amended). A pharmaceutical composition comprising ~~Carbopol®~~ a high molecular weight, cross-linked, acrylic acid-based polymer, propylparaben, methylparaben, propylene glycol, CKPV (SEQ ID NO: 5) dimer, 2 M NaOH and sterile water for injection.

32. (Previously presented). The composition of claim 31 further comprising EDTA.
33. (Previously presented). The composition of claim 31 wherein the CKPV (SEQ ID NO: 5). dimer is at least about 0.1% of the composition.
34. (Currently amended). The composition of claim 31 wherein the Carbopol® high molecular weight, cross-linked, acrylic acid-based polymer is at least about 2% of the composition.
35. (Previously presented). The composition of claim 31 wherein the methylparaben is at least about 0.15% of the composition.
36. (Previously presented). The composition of claim 31 wherein the propylparaben is at least 0.05% of the composition.
37. (Previously presented). The composition of claim 31 wherein the propylene glycol is at least about 10% of the composition.
38. (Previously presented). The composition of claim 32 wherein the EDTA is at least about 0.1% of the composition.
39. (Previously presented). The composition of claim 31 wherein the 2M NaOH is that quantity sufficient to bring the composition to a pH of 4.0+-.0.1.
40. (Previously presented). The composition of claim 31 wherein the sterile water for injection is that quantity sufficient to create a gel.
41. (Currently amended). A pharmaceutical composition comprising 2% of Carbopol® a high molecular weight, cross-linked, acrylic acid-based polymer, 0.05% of propylparaben, 0.15% of methylparaben, 10% of propylene glycol, 0.1% g of EDTA, 2M NaOH in a quantity sufficient to bring the composition to a pH of 4.0+-.0.1, 0.1% of CKPV (SEQ ID NO: 5). dimer and sterile water for injection quantity sufficient to create a gel.
42. (Previously presented). A method of treating urogenital conditions comprising the use of a pharmaceutical composition comprising at least about 2% of Carbopol® a high molecular weight, cross-

linked, acrylic acid-based polymer, at least about 0.05% of propylparaben, at least about 0.15% of methylparaben, at least about 10% of propylene glycol, at least about 0.1% of EDTA, 2M NaOH in a quantity sufficient to bring the composition to a pH of 4.0.+-.0.1, at least about 0.1% of CKPV (SEQ ID NO: 5). dimer and sterile water for injection quantity sufficient to create a gel.